HLA-A2-restricted peptide epitopes of fibroblast activation protein alpha (FAPα) for cancer vaccination
The following invention is a new, peptide based vaccination against genetical stable tumor stroma-associated antigens. Because of significant upregulation of certain proteins (e.g. FAPα, CD105) tumor stroma cells are suitable targets for anti-tumor therapy. This technology employs these specific antigens in the vaccine design to avoid an immunologic attack on normal unaltered cells.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
